Effects of targeted therapy with afatinib (Gitari) and real feedback from patients

Afatinib (Afatinib) is an oral irreversible ErbB family receptor tyrosine kinase inhibitor (TKI), mainly used for advanced non-small cell lung cancer (N SCLC) patients, especially those carrying EGFR-sensitive mutations (such as Del19 or L858R). Its mechanism of action is to irreversibly bind to the receptor tyrosine kinase regions of EGFR, HER2 and HER4, thereby inhibiting the downstream signaling pathways of the receptors, blocking tumor cell proliferation and survival signals, and achieving anti-tumor effects. Compared with the first generation EGFR-TKIs (such as gefitinib and erlotinib), afatinib has an irreversible inhibitory effect and therefore shows certain advantages in some resistance mechanisms, especially in patients with Del19 mutations, showing longer progression-free survival (PFS).

Clinical studies and real-world data have shown that afatinib has significant efficacy in patients with EGFR sensitive mutationsNSCLC. For example, in LUX-Lung 3 and LUX-Lung 6In clinical trials, the median progression-free survival of patients with Del19 mutations reached 11 pan>to 14 months, while patients with L858R mutation are slightly shorter, but it is also significantly better than the chemotherapy regimen. In addition, afatinib has also shown certain efficacy in patients with brain metastases. Its ability to pass through the blood-brain barrier can control brain metastases in some patients, which is an important advantage in the clinical management of patients with advanced NSCLC.

Feedback from real patients shows that afatinib has a certain effect in prolonging survival and improving quality of life. Most patients reported that in the early stages of using afatinib, tumor-related symptoms such as cough, chest pain and dyspnea were relieved, and their physical strength and ability to take care of themselves were improved. At the same time, some patients can maintain good tumor control and delay disease progression during long-term use. However, patient feedback also shows that the side effects of afatinib cannot be ignored. Common adverse reactions include diarrhea, rash, stomatitis and mild to moderate liver function abnormalities, among which diarrhea is the most common side effect that affects quality of life. Some patients need to adjust the dosage or combine supportive treatments (such as rehydration, anti-diarrhea drugs and skin care) to alleviate adverse reactions during use.

For side effect management, clinical practice usually recommends starting with the standard dose (40 mgonce a day) and adjusting the dose according to patient tolerance. For example, if moderate diarrhea or rash occurs, the drug can be discontinued for a short period of time or the dose can be reduced to 30 mg once a day, and the original dose can be restored after the symptoms are relieved. In addition, patients need to regularly monitor blood routine, liver function and kidney function during treatment to detect and deal with abnormalities in a timely manner. In the real world, there are also some patients whose medication compliance is affected by side effects, and they need to rationally arrange dosage and auxiliary medication under the guidance of doctors to maximize long-term treatment effects.

Taken together, afatinib, as a second-generation EGFR-TKI, has a clear targeted therapeutic effect in patients with EGFR mutationsNSCLC, especially for patients with Del19 mutations. Feedback from real patients shows that it has certain advantages in extending progression-free survival, improving quality of life and controlling symptoms, but at the same time side effect management is the key to successful treatment. Through individualized dose adjustment, regular monitoring and adjuvant supportive treatment, patients can achieve better long-term efficacy while minimizing adverse reactions. In the future, with the accumulation of more real-world data, the clinical use strategy of afatinib will be further optimized to provide more precise and safe targeted treatment options for patients with advanced NSCLC.

Reference materials:https://www.drugs.com/